Insulin resistance is the silent driver behind: Type 2 diabetes Metabolic syndrome Polycystic ovary syndrome (PCOS) Non-alcoholic fatty liver disease (NAFLD) Cardiovascular disease The problem
Jensterle M, Ferjan S, Leai L, et al
So, patience is key , but so is proactive management
10.1016/S0140-6736(19)31271-1 Summary Keywords colorectal cancer, gastrointestinal cancer, GLP-1 receptor agonists, liver cancer, meta-analysis, obesity, oncological safety, pancreatic cancer Citation Wali AF, Rangraze I, Khan S, Mufti UB, El-Tanani M and Rizzo M (2026) Reassessing cancer risk with GLP-1 receptor agonists: a comprehensive meta-analysis of gastrointestinal malignancies